HIVE Digital Technologies Ltd. (HIVE) is a Nasdaq-listed data center operator formerly known as HIVE Blockchain Technologies. The company operates green-energy-powered facilities across Canada, Sweden, and Paraguay, and has increasingly positioned itself as a dual-engine business: Bitcoin mining alongside accelerated AI and high-performance computing (HPC) through its BUZZ HPC subsidiary.
Shares recently traded near $2.78, with a 52-week range of roughly $1.73 to $7.84 and a market capitalization around $820 million. That range matters: the stock has already been above the $7 level, so the question is less about whether it is possible in theory and more about whether the company can rebuild the momentum needed to return there.
The $7 mark stands out for several reasons. It is effectively the consensus analyst price target, with the average objective across major firms sitting near $6.95–$7.06. It is also a clean psychological round number, and it sits just below the stock's prior high of $7.84, making it a natural milestone investors monitor on the way back toward previous peaks. Because the company is unprofitable, traditional earnings-based valuation is not meaningful, leaving revenue growth and future contract momentum as the main anchors for the bull case.
The core of the bullish argument is the shift toward AI infrastructure. HIVE's BUZZ HPC unit recently signed a five-year, roughly $350 million GPU cloud contract with an investment-grade enterprise customer, expected to generate about $70 million in annualized revenue. Combined with an earlier sovereign AI agreement with Bell AI Fabric, BUZZ HPC's contracted annual recurring revenue (ARR) has risen to roughly $180 million, approaching the company's stated goal of $200 million in GPU cloud ARR.
Management has also pointed to a substantial development pipeline—approximately 400 megawatts of data center capacity in Canada—and the potential for a colocation agreement at its Boden, Sweden facility. If these projects convert from pipeline to contracted revenue, they would reinforce the higher-margin, recurring-revenue story that underpins analyst targets as high as $10.
Several obstacles stand between the current price and $7. HIVE remains unprofitable, recently posting a quarterly loss of $0.54 per share versus a consensus estimate of a $0.21 loss, with revenue also slightly below expectations. A large net loss was driven partly by non-cash items, including a provision tied to a long-running Swedish tax dispute, but sustained losses still pressure sentiment.
Funding the AI buildout also carries dilution risk. The company has used a zero-coupon convertible bond and equipment financing, and further capital raises could weigh on the share count. Meanwhile, insider activity has leaned toward selling—roughly $3.3 million in insider sales over a recent three-month period with no reported buying—a signal some investors interpret cautiously. Finally, HIVE retains meaningful Bitcoin mining exposure, so cryptocurrency price swings continue to influence results even as the AI business grows.
The analyst community leans clearly bullish, with a consensus rating of "Moderate Buy" to "Strong Buy" and an average price target near $7. H.C. Wainwright has reiterated a Buy rating with a $7 target, while Canaccord Genuity holds a $10 objective, B. Riley Securities and UBS sit near $8, and Chardan Capital initiated coverage with a $7.50 target. KBW is the notable outlier, carrying a Hold rating with a $4.50 target. This range illustrates that while most firms see substantial upside, the more conservative estimate still falls well short of $7.
From a technical analysis perspective, the $7.84 prior high is the most significant resistance area, and $7 acts as a psychological and consensus milestone just beneath it. On the downside, the recent $2.50–$2.60 zone has provided support, with the 52-week low of $1.73 marking the extreme downside. The stock carries a very high beta near 3.8, meaning it tends to move far more dramatically than the broader market in both directions—a key consideration given the distance still required to reach $7.
For traders looking to monitor HIVE and thousands of other stocks and ETFs, Tickeron's AI Daily Buy/Sell Signals offer an AI-driven approach to tracking changing market conditions. The product continuously analyzes technical behavior and market data to generate Buy, Sell, or Hold signals, helping users identify emerging opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Whether you are watching HIVE's path back toward $7 or evaluating other names, these signals can serve as a useful complement to your own research.
A return to the $7 level is realistic but not assured. The strongest support comes from a clearly bullish analyst consensus, a rapidly scaling AI and HPC business with contracted revenue visibility, and the fact that HIVE has already traded above this level in the past year. Against that, persistent losses, potential dilution, insider selling, execution risk on capital-intensive deployments, and lingering Bitcoin exposure all stand in the way. Investors should monitor progress toward the $200 million ARR goal, any new AI contracts, financing terms, and the trajectory toward profitability. Whether HIVE can reclaim $7 will ultimately depend less on technicals and more on whether the company can convert its growing AI pipeline into sustained, profitable revenue.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HIVE has been closely correlated with KEEL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if HIVE jumps, then KEEL could also see price increases.
| Ticker / NAME | Correlation To HIVE | 1D Price Change % | ||
|---|---|---|---|---|
| HIVE | 100% | +1.97% | ||
| KEEL - HIVE | 76% Closely correlated | +3.58% | ||
| CIFR - HIVE | 73% Closely correlated | +2.13% | ||
| COIN - HIVE | 73% Closely correlated | -4.18% | ||
| CLSK - HIVE | 72% Closely correlated | +0.87% | ||
| RIOT - HIVE | 69% Closely correlated | +3.12% | ||
More | ||||